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Aims A non-invasive gene-expression profiling (GEP) test for rejection surveillance of heart transplant recipients originated in
the USA. A European-based study, Cardiac Allograft Rejection Gene Expression Observational II Study (CARGO II),
was conducted to further clinically validate the GEP test performance.
Methods
and results
Blood samples for GEP testing (AlloMapw, CareDx, Brisbane, CA, USA) were collected during post-transplant surveil-
lance. The reference standard for rejection status was based on histopathology grading of tissue from endomyocardial
biopsy. The area under the receiver operating characteristic curve (AUC-ROC), negative (NPVs), and positive predictive
values (PPVs) for the GEP scores (range 0–39) were computed. Considering the GEP score of 34 as a cut-off (.6 months
post-transplantation), 95.5% (381/399) of GEP tests were true negatives, 4.5% (18/399) were false negatives, 10.2% (6/59)
were true positives, and 89.8% (53/59) were false positives. Based on 938 paired biopsies, the GEP test score AUC-ROC
for distinguishing ≥3A rejection was 0.70 and 0.69 for ≥2–6 and.6 months post-transplantation, respectively. Depend-
ing on the chosen threshold score, the NPV and PPV range from 98.1 to 100% and 2.0 to 4.7%, respectively.
Conclusion For ≥2–6 and .6 months post-transplantation, CARGO II GEP score performance (AUC-ROC ¼ 0.70 and 0.69) is
similar to the CARGO study results (AUC-ROC ¼ 0.71 and 0.67). The low prevalence of ACR contributes to the high
NPV and limited PPV of GEP testing. The choice of threshold score for practical use of GEP testing should consider
overall clinical assessment of the patient’s baseline risk for rejection.
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Introduction
A non-invasive gene-expression profiling (GEP) test (AlloMapw,
CareDx, Brisbane, CA, USA) was first demonstrated to discriminate
acute cellular rejection from quiescence in cardiac transplant recipi-
ents in a US-based clinical study, Cardiac Allograft Rejection Gene
Expression Observational Study (CARGO).1,2 Estimates of the
negative predictive value (NPV) associated with a GEP score
†These authors contributed equally to this work and shared co-first authorship.
*Corresponding author. Tel: +32 16 3 44251, Fax: +32 16 3 44240, Email: johan.vanhaecke@uzleuven.be
& The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
doi:10.1093/eurheartj/ehv682
European Heart Journal (2016) 37, 2591–2601
; online publish-ahead-of-print 7 January 2016
below a nominal threshold level (e.g. 34) were refined during re-
analyses of the CARGO dataset during the US Food and Drug Ad-
ministration (US FDA) regulatory clearance of AlloMap as a de novo
510 k in vitro diagnostic test (see Supplementary material online, Ap-
pendix S1). The randomized controlled Invasive Monitoring Attenu-
ation through Gene Expression (IMAGE) study showed the
non-inferiority of clinical outcomes in patients managed with GEP
for rejection surveillance compared with patients managed with
conventional biopsy surveillance.3 The International Society of
Heart and Lung Transplantation (ISHLT) guidelines for care of heart
transplant recipients recommend that the GEP test can be used as a
non-invasive method for ruling out moderate to severe acute cellu-
lar rejection in asymptomatic patients (i.e. without clinical suspicion
of allograft dysfunction).4 The CARGO II study was designed to
evaluate GEP in a different population from CARGO. There are
very few published clinical validation studies for commercially avail-
able diagnostic tests based on gene-expression profiling of periph-
eral blood, and AlloMap is the only product of this kind for use in
heart transplantation.5
Therefore, the objective of the current report was to validate the
clinical performance of the gene-expression profiling technology in
an entirely independent large study population. The hypothesis of
this study is that the GEP test can discriminate acute cellular rejec-
tion from non-rejection status, with high negative predictive values
and overall accuracy similar to that previously demonstrated in
CARGO. Antibody-mediated rejection cases were not included in
these computations. The GEP test performance was evaluated in
two post-transplantation time windows: ≥2–6 months and .6
months, because prior evidence had indicated that the risk of rejec-
tion and performance of the GEP test may both be sensitive to time
post-transplantation.1,6,7
Methods
CARGO II study design
The CARGO II was a prospective, observational, multi-centre study
with blood samples and associated clinical data collected from follow-up
visits of cardiac transplantation recipients from May 2005 through Feb-
ruary 2009 (ClinicalTrials.gov Identifier: NCT00761787). The 17 partici-
pating centres (13 Western European and 4 North American) obtained
Institutional Review Board approvals and signed written informed con-
sents from participating patients. The study was conducted in accord-
ance with the Good Clinical Practices and Declaration of Helsinki.
Venous blood was collected at clinic visits during which heart trans-
plant recipients underwent long-term ongoing rejection surveillance,
with or without endomyocardial biopsy (EMB). The blood samples
were collected before EMB. In general, patients were asked not to drink
or eat anything within 8 h before the procedure. An outline of the clin-
ical information collected at each visit, including patient inclusion and ex-
clusion criteria, and sample collection procedures, is provided in
Supplementary material online, Appendix S2.
Reference standard for rejection status
The reference standard for rejection status was the histology-based re-
jection grade (using the ISHLT 1990 grades: 0, 1A, 1B, 2, 3A, 3B, or 4) for
heart tissue obtained from an EMB performed on the same day as the
collection of blood for the GEP test.8 In 2005, the grading system was
revised as follows: Grade 0R-no rejection (no change from the 1990
grading system), Grade 1R-mild rejection (1990 Grades 1A, 1B,
and 2), Grade 2R-moderate rejection (1990 Grade 3A), and Grade
3R-severe rejection (1990 Grades 3B and 4).9 In routine clinical practice,
patient care decisions are most strongly influenced by findings of rejec-
tion grades ≥3A (2R), which usually lead to a treatment intervention.
The histopathology grade is rendered by the local pathologist, who
has viewed the histology slides with light microscopy. In the CARGO
II study, a subset (see below) of all locally graded biopsy slides was
also sent for review by three other pathologists. The intention of this
independent assignment of rejection grades by a central panel of pathol-
ogists was to enhance the accuracy of the reference standard for rejec-
tion that was used to judge the performance of the GEP test.10,11
Because of the high proportion of local EMB scores with Grade 0, and
the limited volume capacity for independent scoring by the reviewing
central pathologists, only one local rejection Grade 0 sample from
each subject was sent for central pathology reading; if a subject had
more than one sample with a local biopsy grade of 0, then one of the
samples was chosen at random. At most, only one Grade 1A sample
from each subject was sent for central pathology reading; if a subject
had more than one sample with a local biopsy grade of 1A, then one
of the samples was chosen at random. All samples that had local biopsy
grades of 1B, 2, and 3A or higher were sent for the independent central
pathology grading. For this report, each rejection case was qualified for
use as a reference standard of rejection if a moderate or more severe
grade of rejection, [i.e. ISHLT 1990 grade of ≥3A (2R)] was reported
by the local pathologist and this grade ≥3A (2R) was independently
confirmed by at least one of three central reviewing pathologists. All
other centrally reviewed biopsy slides were classified as quiescent (i.e.
Grade 0 assigned by the local pathologist and at least 2 of 3 central
pathologists) or other non-rejection cases (i.e. did not meet either
the criteria for classification as quiescent or rejection). All samples
that had central pathology results and GEP score results were included
in the analyses.
Methodology of gene-expression profiling
For the GEP test, a whole blood sample was collected into a BD Vacu-
tainerwCPTTM Cell Preparation tube (Becton Dickinson, NJ, USA) with
sodium citrate anticoagulant (CPT tube). Peripheral blood mononuclear
cells were isolated, lysed by RLT buffer (Qiagen) and the released ribo-
nucleic acid (RNA) was stabilized and frozen. Following shipment to the
CareDx reference laboratory in Brisbane, CA, USA, RNA was further
purified from the lysate; finally, complementary deoxyribonucleic acid
(cDNA) was generated for use in the GEP test. The GEP test was con-
ducted in the CareDx Clinical Laboratory Improvement Amendments
(CLIA)-certified laboratory. The test uses real-time polymerase chain
reaction (RT–PCR) to quantitate expression levels of a preselected pa-
nel of 20 genes: 11 genes informative about allograft rejection and 9
genes for normalization and quality control, used in the calculation of
a GEP logarithmic score that ranges from 0 to 39, Supplementary mater-
ial online, Appendix S3.1
Sample selection
The blood samples included in this study conformed to the following in-
clusion criteria: obtained at least 55 days post-transplantation; .30 days
after transfusion of blood products; .21 days after administration of
≥20 mg/day of prednisone; and .60 days after treating a prior rejection.
Statistical analysis
To calculate the GEP score sensitivity (ability to detect acute cellular re-
jection) and specificity (ability to detect the absence of rejection) and
generate an associated area under the receiver operating characteristic
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(AUC-ROC) curve, positive predictive value (PPV), and NPV, each GEP
sample was correlated to a paired, histology-based rejection grade
(using the ISHLT 1990 grades: 0, 1A, 1B, 2, 3A, 3B, or 4 or equivalent
ISHLT 2005 grades) for heart tissue obtained from an EMB performed
on the same day.8,9
The main metric for validating the GEP test performance was the
AUC-ROC, which is a widely used metric for new screening test
discrimination.12,13 In early 2008, during the regulatory clearance of
AlloMap as a FDA 510 k in vitro diagnostic test, the GEP test perform-
ance characteristics from the original CARGO study were reanalysed
in cooperation with reviewing statisticians from the US FDA. The main
change in the FDA-guided analyses compared with the methods used
in the Deng 2006 publication was that all mild (i.e. ,moderate [grade
3A (2R)]) rejection cases were included in the FDA-guided analyses
which thereby include the full intended use population. Incorporating
these mild rejection cases is called an intent-to-diagnosis (ITD) analysis
(the analog of intent-to-treat or ITT analysis for randomized clinical
trials of therapeutics). All centrally graded samples including all
non-rejection samples (i.e. both quiescent and other samples that
did not qualify to be classified as rejection) were included in the ana-
lysis; Supplementary material online, Appendix S1. The current CAR-
GO II analyses use the same FDA-recommended methodology that
was used in the analyses of the CARGO data: AUC-ROC of GEP score
was estimated using a non-parametric method proposed by Obu-
chowski,14 altered slightly to account for the multiple records per
subject.
The AUC-ROC and 95% confidence intervals were calculated using a
bootstrap method for the data overall and also by time period: ≥2–6
months (≥55–182 days) post-transplantation and .6 months (.182
days) post-transplantation.
Clinical performance metrics were further characterized by comput-
ing the NPV and PPV for acute cellular rejection for each GEP ordinal
score from 12 to 39. These characteristics were computed for two
time periods post-transplantation: ≥2–6 months and .6 months.
The calculation of NPV and PPV involved an adjustment for preva-
lence of rejection, since not all local Grades 0 and 1A biopsies were
sent for central pathology, as described. The adjustment was applied
separately to the different time periods post-transplantation. The ad-
justed prevalence calculation method is shown in the statistical appen-
dix, Supplementary material online, Appendix S4.
Logistic mixed-effects models were used to predict rejection status
from GEP score, both in the absence and in the presence of other clinical
variables (age, gender, primary indication for transplant, cytomegalovirus
status, and pre-transplant use of a left ventricular assist device).
Minimization of bias
The study used a prospective design in which the blood samples and as-
sociated heart biopsy slides were selected from patients enrolled in the
CARGO II Study. Sample labels were encrypted and the lab technicians
were blinded to the patient data associated with each sample, minimiz-
ing any operator bias in determination of the GEP test scores.
Biopsy slides were de-identified prior to centralized pathology review
and grading. Since patients may have more than one sample, the method
of Emir et al.15 was used to analyse the data. This method assigns a
weight to each sample based on the number of samples from the
same patient within a category (rejection or non-rejection).
Results
From the total CARGO II enrollment, 499 patients had 1579 visits
with paired EMB histopathology rejection grades and GEP scores
that met inclusion criteria for the study analyses (Figure 1). Patients
were predominantly Caucasian (89%), male (79%), and 50.8 years
old on average, at the time of transplantation (Table 1). The first
study visit occurred prior to 6 months post-transplantation in
88% of the patients. Moderate to severe acute cellular rejection
was reported by the local pathologists in 53/1645 (3.2%) of biopsies
at ≥2–6 months post-transplantation [representing 47/468 (10.0%)
of patients] and in 53/1679 (3.2%) of biopsies at .6 months post-
transplantation [representing 41/518 (7.9%) of patients]. The preva-
lence of moderate to severe grade rejection was 106/3325 (3.2%) in
the population as a whole. When the rejection was also required to
be confirmed by at least one central pathologist [(i.e. rejection was
defined as 1 local grade ≥3A (2R) plus ≥1 central grade ≥3A (2R)],
the prevalence was reduced to 2.0%.
The patient population with histopathology slides selected for
independent central panel pathology rejection grading included
328 patients with 480 GEP test scores at ≥2 –6 months post-
transplantation, while 322 patients provided 458 GEP test scores
at .6 months post-transplantation. Of a total of 938 centrally
graded biopsies, 46 (4.9%) were deemed rejections, whereas 246
(26.2%) were classified as quiescent. The remaining 646 (68.9%) bi-
opsies were intermediate (i.e. did not meet the criteria to qualify as
either a rejection or a quiescent reference standard criteria). The
implications of this subset with discordant grades from the pathol-
ogists are addressed in the discussion section of this paper. Of the
938 biopsies sent for central review, 919 were surveillance biopsies,
9 were for suspected rejection, and 10 were performed for other
reasons. Out of the 46 centrally confirmed rejections, 43 were
from surveillance biopsies, and 3 were biopsies performed because
of suspected rejection. The three clinically suspected rejections that
were confirmed by biopsy had GEP scores of 29, 34, and 37. The
average GEP score of samples taken at the time of a biopsy-proven
≥3A (2R) rejection was significantly higher (28.3, SD 5.3) than the
average GEP score of all samples taken at times when the biopsy re-
vealed a non-rejection status (25.6, SD 5.9), P ¼ 0.001. Of the 938
centrally graded biopsies, the distribution of local grades was as fol-
lows (n, %): Grade 0 (384, 40.9%); Grade 1A (245, 26.1%); Grade 1B
(68, 7.2%); Grade 2 (131, 14.0%); Grade 3A (70, 7.5%); Grade 3B
(5, 1%); Grade 4 (1, ,1%); local grades were not available for 34
(3.6%) biopsies. Of the 109 biopsies that were graded ≥3A (2R)
by at least one central reviewer, 63 (58%) received a local grade
of 2 or less (Table 2).
The mean AUC-ROC for the GEP test scores in the ≥2–6
months post-transplantation period was 0.70 with 95% confidence
interval from 0.67 to 0.73. The mean AUC-ROC for the GEP test
scores for the .6 months post-transplantation period was 0.69
with 95% confidence interval from 0.66 to 0.72. The GEP scores
by time post-transplant are shown in Figure 2.
The CARGO II-based GEP NPV and PPV performance character-
istics are shown in Tables 3 and 4. A GEP test score of ≥34 (often
used in clinical practice as a threshold score for patients who are.6
months post-transplantation) corresponded to histology-based
grade ≥3A (2R) rejection with a PPV of 4.0% at months ≥2–6 post-
transplantation, and 4.3% at .6 months post-transplantation. The
NPVs were 98.4% at months ≥2–6 post-transplantation and
98.3% at .6 months post-transplantation. In both time windows,
the NPVs increased from 98.3 to .99.0% for decreasing threshold
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values below 34. The corresponding PPVs decreased from 4.3 to
2.1. The number (and %) of patients with centrally adjudicated
≥3R (2R) rejection below or above GEP score of 34 is presented
in Table 5. Using the score of 34 as a cut-off for patients who are
.6 months post-transplantation, 95.5% (381/399) of GEP tests
were true negatives, 4.5% (18/399) were false negatives, 10.2%
(6/59) were true positives, and 89.8% (53/59) were false positives.
The probability of rejection using a threshold of,34 as a negative
test moves from 3.2% pretest to 1.7% post-test, i.e. the NPV goes
from 96.8% without the GEP test to 98.3–98.4% with a negative
test, which occurred in 82.5–85% of the population. For 15% of
positive tests, the patients may be considered for a follow-up biopsy,
96% of which will be negative.
In the univariate model, GEP score and age were significantly as-
sociated with ≥3A (2R) acute cellular rejection (Table 6). In the
multivariate model, after adjustment for clinical variables, a decreas-
ing GEP score (P ¼ 0.004) and age ≥54 years (P ¼ 0.008) were as-
sociated with decreased probability of ≥3A (2R) rejection.
Subgroup analyses of clinical variables for association of GEP score
and ≥3A (2R) acute cellular rejection are shown in Table 7.
Discussion
The performance characteristics of GEP scores to discriminate
acute cellular rejection from non-rejection status of heart transplant
recipients in CARGO II are very similar to the performance of GEP
scores reported from CARGO, based on similar FDA-recom-
mended analyses applied to these two independent data sets.6
This additional independent clinical validation is important, as such
confirmatory studies are rare in the field of molecular diagnostic
tests based on gene-expression profiling technologies; the hypoth-
esis that the AlloMap GEP signature generated from assay of mRNA
purified from circulating peripheral blood cells is informative of the
immune status of the allograft is thus further validated by the results
in this report.
The CARGO II study population is similar to most heart trans-
plant study cohorts in demographic composition,16 but has a higher
percentage of Caucasians than the US-based CARGO study. The
3.2% prevalence of moderate to severe rejection found in locally
graded biopsies and estimated 13% incidence of rejection in patients
is lower than the 66% rejection rate in patients reported during the
Figure 1 Source of patients and samples included in the area under the receiver operating characteristic curve calculations and modelling of
negative predictive value (NPV) and positive predictive value (PPV) performance of gene-expression profiling in the study population. Local biopsy
(and pathology grading): local centre’s pathologist’s grade of rejection of an endomyocardial biopsy and a paired blood sample for gene-expression
profiling available for the patient visit. Central pathology review: a central panel of pathologists provided independent grading of rejection of the
endomyocardial biopsy slides and a paired blood sample for gene-expression profiling available for the patient visit. Note: the negative predictive
value and positive predictive value calculations used the local biopsy findings to adjust for prevalence rates for rejection. The central biopsies were
used to ascertain the reference standards for Grade 3A or more severe rejection grades vs. lesser grades of rejection.
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first year post-transplantation in the often-cited Kubo article.17 The
lower prevalence of acute cellular rejection in CARGO II results
compared with estimates from experiences 20 years earlier may
be attributable to more effective contemporary immunosuppres-
sion regimens. This prevalence of biopsy-based moderate to severe
rejection grades in the current study was consistent with the more
recent report of a similar population undergoing biopsies in the first
year post-transplantation: biopsy-based acute rejections were
reported to range from 1.9% (35 of 1875 biopsies) to 3.1% (58 of
1854 biopsies).18
The current report finds that rates of rejection were similar in the
early post-transplantation months (3.2% for months ≥2 to 6) com-
pared with the later time post-transplantation (3.2% . Month 6).
However, it is possible that the biopsies performed after Month 6
post-transplantation may have been performed more often due to
clinical suspicion of rejection, whereas biopsies performed earlier
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Table 1 Baseline characteristics of study patients
Characteristics n 5 499a n 5 41
rejections
n 5 431
non-rejection
P-values
Age, years, mean (standard deviation) 50.8 (13.7) 46.1 (13.9) 51.2 (13.5) 0.011
Male sex 393 (79) 34 (83) 338 (78) 0.689
Race
Caucasian 443 (89) 35 (85) 386 (90) 0.427
African American 16 (3) 3 (7) 13 (3) 0.154
Asian 11 (2) 1 (2) 8 (2) 0.562
Hispanic 9 (2) 1 (2) 8 (2) 0.562
Others 20 (4) 1 (2) 16 (4) 1.000
Non-Caucasian 56 (11) 6 (15) 45 (10) 0.427
Indication for cardiac transplantation
Coronary artery disease 185 (37) 16 (37) 160 (37) 0.866
Non-ischaemic cardiomyopathy 256 (51) 22 (54) 228 (53) 1.000
Other indications 38 (8) 3 (7) 43 (10) 0.785
Unknown indication 20 (4) 0 (0) 0 (0) –
Interval between transplantation and study enrollment
Enrolled prior to transplantation 70 (14) 6 (15) 62 (14) 1.000
,6 months 367 (7) 29 (71) 323 (75) 0.575
6–12 months 24 (5) 2 (5) 15 (3) 0.652
13–36 months 20 (4) 2 (5) 18 (4) 0.689
37–60 months 2 (0) 0 (0) 2 (0) 1.000
.60 months 16 (3) 2 (5) 11 (3) 0.314
Cytomegalovirus serology (IgG) status
Donor and recipient positive 150 (30) 13 (32) 129 (30) 0.859
Donor and recipient negative 78 (16) 5 (12) 68 (16) 0.656
Donor positive and recipient negative 84 (17) 8 (20) 72 (17) 0.663
Donor negative and recipient positive 113 (23) 8 (20) 99 (23) 0.700
Unknown 74 (15) 7 (17) 63 (15) 0.647
Use of ventricular assist device before transplantation 118 (24) 6 (15) 110 (26) 0.133
Induction therapy (any) 384 (77) 34 (83) 295 (68) 0.074
Immunosuppressive therapy, at any time during study
Cyclosporin A 298 (60) 29 (71) 256 (59) 0.183
Tacrolimus 309 (62) 24 (59) 265 (61) 0.739
Mycophenolate mofetil or mycophenolic acid 421 (84)
Prednisone 436 (87) 39 (95) 394 (91) 0.561
Left ventricular ejection fraction at first study visit, mean % (standard deviation) 64.1 (9.6) 63.1 (8.7) 64.7 (9.5) 0.301
Values are n (%) unless indicated otherwise.
IgG, immunoglobulin G.
aTwenty-seven patients did not have central pathology readings.
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than Month 6 were probably more often conducted for surveillance
of asymptomatic patients. This ascertainment bias is discussed fur-
ther in the limitations section below.
The local biopsy-based rejection cases [grades ≥3A (2R)] that
were confirmed by the independent panel of central pathologists
in the current study served as the key reference standard for
rejection that was used to judge the diagnostic performance of
the GEP score. The reason these central pathologist confirmed re-
jections represent the most important factor in determining the
clinical performance of the GEP test is that a biopsy finding of a re-
jection grade ≥3A (2R) generally calls for treatment of the patient,
whereas for lower rejection grades or quiescence, there is the op-
tion to observe the patient’s interval clinical progress at a future visit.
All 646 (68.9%) centrally graded biopsies that were by default as-
signed to an intermediate class (i.e. those biopsies that did not
meet criteria to serve as rejection or quiescence reference stan-
dards) were included in the computation of the NPV and PPV; these
cases were categorized as ‘non- rejection’. The relatively large num-
ber of biopsies assigned to this intermediate class reflects the high le-
vel of discordance between pathologists’ readings in this large
proportion of biopsies with disparate reader scores of Grade 0,
Grade 1A, Grade 1B, and Grade 2. Previous analysis of the CARGO
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Agreement between local and central
pathology grades for rejection
Local grades Central grades
≥3A (2R) rejection <3A (2R)
≥3A (2R), n/n (%) 46/76 (60.5) 30/76 (39.5)
,3A (2R), n/n (%) 63/862 (7.3) 799/862 (92.7)
Figure 2 Gene-expression profiling score by the time post-transplant. The number of gene-expression profiling tests between Month 12 and
Month 13 post-transplant ranged from 24 (Month 11) to 128 (Month 3). The number of gene-expression profiling tests between Month 14 and
Month 24 post-transplant ranged from 2 (Month 24) to 11 (Month 15).
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II data set demonstrated that both within the panel agreement and be-
tween the panel and local pathologists agreement decreased with in-
creasing category of severity of rejection grade (from 65% to
28%).10 In that study, an EMB graded ≥3A (2R) by one pathologist
was unlikely to be equally graded by a given second pathologist. The
observed low agreement between pathologists of 28% for grade ≥3A
(2R) EMB readings indicates the uncertainty of biopsy-based diagnosis
of rejection, albeit this method remains the ‘gold’ standard for asses-
sing the rejection status of a transplanted heart. In the current study,
in 40% of cases (Table 2), a central pathologist ‘downgraded’ the lo-
cal pathologists’ grades of ≥3A (2R) to a grade ,3A (2R). The ten-
dency for local pathologists to assign grades of ≥3A (2R) more often
than central pathologists may be attributable to the local pathologist
being influenced by clinical information that is not available to the cen-
tral reviewers. The discordance of grade assignment by local and cen-
tral pathologists is also attributable to the diagnosis depending on
subjective pattern recognition as well as potential tissue sampling er-
rors and/or the non-specificity of the histology findings.10,11
A major reason the ISHLT 2005 rejection grading re-classification
combined the several 1990 subcategories of intermediate rejection
grades is that there is uncertainty of the clinical relevance and prog-
nostic implications of these intermediate grades. Most often, a bi-
opsy finding of an intermediate grade will not lead to treatment
or other interventional actions: follow-up depends on the clinical
context. The GEP test is not designed to correlate with or classify
intermediate grades of rejection. However, a sub-analysis of the ori-
ginal CARGO data demonstrated that GEP scores discriminate
moderate to severe rejection from mild rejection (Grades 1A
and 2). A subgroup of mild rejection cases, defined as Grade 1B ac-
cording to the 1990 grading system, share a molecular signature
more consistent with moderate to severe rejection.19 The clinical
relevance of these intermediate grades of rejection is not part of
the current CARGO II study and remains to be defined.
Because the AUC-ROC is easy to understand and it does not rely
on specific thresholds, it is commonly used to measure the accuracy
of a diagnostic test.13 Values for the AUC-ROC range from 0.5 (un-
informative) to 1.0 (perfect discrimination). An example of
AUC-ROC in the cardiovascular area is The Framingham Risk Score,
which is based on traditional cardiovascular risk factors.13 This score
yields an AUC-ROC of 0.68, based on age and gender, and goes up
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Table 3 CARGO II GEP test performance results in the ≥2–6 months post-transplantation period
GEP score Scores below threshold n (%) PPV (%) NPV (%) Sensitivity (%) Specificity (%)
12 14 (2.9) 1.9 100.0 100.0 3.5
13 21 (4.4) 2.0 100.0 100.0 5.0
14 31 (6.5) 2.0 100.0 100.0 7.1
15 39 (8.1) 2.1 100.0 100.0 9.3
16 50 (10.4) 2.1 100.0 100.0 11.7
17 58 (12.1) 2.1 100.0 100.0 13.3
18 71 (14.8) 2.1 99.4 95.0 15.9
19 83 (17.3) 2.0 99.0 90.0 17.9
20 95 (19.8) 2.0 98.8 87.5 20.2
21 111 (23.1) 2.1 99.0 87.5 23.9
22 133 (27.7) 2.3 99.2 87.5 28.2
23 155 (32.3) 2.1 98.7 77.5 32.7
24 182 (37.9) 2.0 98.3 65.0 38.0
25 201 (41.9) 2.1 98.4 65.0 42.0
26 223 (46.5) 2.1 98.4 60.0 47.2
27 256 (53.3) 2.1 98.3 52.5 53.6
28 295 (61.5) 2.1 98.3 42.5 61.9
29 321 (66.9) 2.1 98.3 37.5 67.3
30 349 (72.7) 2.6 98.4 37.5 73.2
31 373 (77.7) 3.1 98.5 37.5 77.7
32 393 (81.9) 3.1 98.4 30.0 81.9
33 409 (85.2) 3.9 98.5 30.0 85.8
34 425 (88.5) 4.0 98.4 25.0 88.7
35 443 (92.3) 2.3 98.2 10.0 91.9
36 453 (94.4) 3.1 98.2 10.0 94.1
37 460 (95.8) 4.2 98.2 10.0 95.6
38 475 (99.0) 0.0 98.1 0.0 98.9
39 479 (99.8) 0.0 98.1 0.0 99.7
GEP test scores range from 0 to 39.
CARGO, Cardiac Allograft Rejection Gene Expression Observational Study; GEP, gene-expression profiling; NPV, negative predictive value; PPV, positive predictive value.
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to 0.75 when other risk factors are added. The CARGO II GEP
AUC-ROC of 0.70 (95% confidence interval 0.67 to 0.73) and
0.69 (95% confidence interval 0.66 to 0.72) for patient samples
from the ≥2–6 months and .6 month time windows, respectively,
were comparable to the CARGO results (see Supplementary ma-
terial online, Appendix S1).6 The limited sensitivity and PPV of the
GEP score for a histology diagnosis of acute cellular rejection are
similar to the sensitivity and PPV reported between expert pathol-
ogists.10,11 Observed concordance between local and collaborating
study pathologists for EMB scoring was 28% for grade ≥3A (2R) in
the CARGO II study10 and 40% for grade ≥3A (2R) using 1990
ISHLT grading in the CARGO Study.11 This circumstance of a low
concordance of rejection grades between expert pathologists has
also been reported with interpretation of biopsies from trans-
planted kidneys.20,21 Kidney transplant researchers who are seeking
to develop molecular signatures that are correlated to histology ref-
erence standards of rejection have observed a problem that applies
also to heart transplant: the ‘reference standard-related bias’. The
new test, whether based on a molecular classifier or the opinion
of a second pathologist, will not agree perfectly with the existing ref-
erence standard (the opinion of a different pathologist), when there
is a high degree of subjectivity involved in the assignment of the ref-
erence standard. ‘Noise’ and the associated range of uncertainty
within heart (or other transplanted organ such as kidney) tissue
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Table 4 CARGO II GEP test performance results in the >6 months post-transplantation period
GEP score Scores below threshold n (%) PPV (%) NPV (%) Sensitivity (%) Specificity (%)
12 6 (1.3) 2.0 100.0 100.0 1.5
13 9 (2.0) 2.0 100.0 100.0 2.1
14 14 (3.1) 2.0 98.5 97.7 3.1
15 19 (4.1) 2.0 98.9 97.7 4.0
16 27 (5.9) 2.1 99.2 97.7 5.9
17 32 (7.0) 2.1 99.3 97.7 7.0
18 43 (9.4) 2.2 99.5 97.7 9.7
19 55 (12.0) 2.2 99.6 97.7 12.1
20 62 (13.5) 2.3 99.7 97.7 14.0
21 79 (17.2) 2.4 99.7 97.7 17.8
22 95 (20.7) 2.5 99.8 97.7 21.7
23 108 (23.6) 2.6 99.8 97.7 25.0
24 130 (28.4) 2.8 99.8 97.7 30.3
25 146 (31.9) 2.8 99.6 93.2 33.3
26 165 (36.0) 3.0 99.6 93.2 38.7
27 198 (43.2) 3.2 99.4 86.4 46.5
28 220 (48.0) 3.1 99.1 77.3 51.2
29 251 (54.8) 3.4 99.0 72.7 57.4
30 294 (64.2) 3.8 98.9 63.6 67.6
31 331 (72.3) 4.4 98.8 54.5 76.1
32 357 (77.9) 4.6 98.6 45.5 80.6
33 378 (82.5) 3.5 98.3 27.3 84.5
34 399 (87.1) 4.3 98.3 25.0 88.8
35 418 (91.3) 2.8 98.1 11.4 92.0
36 439 (95.9) 4.7 98.1 9.1 96.2
37 450 (98.3) 0.0 98.0 0.0 98.2
38 454 (99.1) 0.0 98.0 0.0 99.4
39 455 (99.3) 0.0 98.0 0.0 99.8
GEP test scores range from 0 to 39.
CARGO, Cardiac Allograft Rejection Gene Expression Observational Study; GEP, gene-expression profiling; NPV, negative predictive value; PPV, positive predictive value.
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 True positive, false positive, true negative,
and false negative rates based on GEP threshold score
≥34
≥3A (2R) <3A (2R)
GEP score ≥2–6 months post-transplant
≥34, n/n (%) 5/55 (9.1) TP 50/55 (90.9) FP
,34, n/n (%) 17/425 (4.0) FN 408/425 (96.0) TN
GEP n .6 months post-transplant
≥34, n/n (%) 6/59 (10.2) TP 53/59 (89.8) FP
,34, n/n (%) 18/399 (4.5) FN 381/399 (95.5) TN
Example: 5/55, 5 ¼ number of cases with GEP score ≥34 and ≥3A (2R) rejection;
55 ¼ sum of ≥3A (2R) and ,3A (2R) rejections with GEP score of ≥34.
GEP, gene-expression profiling; FN, false negative; FP, false positive; TN, true
negative, TP, true positive.
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histology is intrinsic, due to a variety of causes as summarized
above.9,10,21 To transcend this limitation of histology, it may be use-
ful to correlate the performance of GEP use to alternative clinical
endpoints such as organ function; this approach is outside the scope
of the current paper, but the potential of such approaches has been
reported.22,23
Although CARGO II, like CARGO, was a landmark study in
cumulative number of patients and surveillance samples/visits col-
lected, there was a low cumulative incidence of observed rejections.
The relatively small number of rejection episodes and the spread of
these cases over a wide post-transplantation time range likely con-
strain the GEP test performance characteristics (i.e. failure of GEP
test to achieve statistical significance in some of our subgroup
analyses could be attributed to imbalance in the dataset and to
the very low sample size for some covariates, Table 7). The GEP
score was an equally significant predictor of acute cellular rejection
(≥2R) in both univariate and multivariate models (Table 6). Never-
theless, the discovery of asymptomatic rejection may be enhanced if
a GEP score exceeding threshold (i.e. 34) is used to lead to perform-
ance of a biopsy, since the GEP score PPV in this circumstance may
be approximately two-fold higher than the prevalence of rejection
in the surveillance population.
The AUC-ROC was analysed in two time windows, because the
mean GEP score in a large, unselected, patient population tends to
gradually rise from Month 2 to Month 6; this upward trend is less
pronounced from Month 7 to 12; the mean GEP score reaches a
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 6 Univariate and multivariate analyses for variables predictive of acute cellular rejection ≥3A (2R)
Characteristics Univariate Multivariate
Coefficienta P-values Coefficienta P-values
Gene-expression profiling score (incremental unit increase by one) 0.08 0.004 0.08 0.004
Age, ≥54 20.02 0.044 20.03 0.008
Gender, male 0.09 0.811 0.25 0.549
Primary indication for cardiac transplantation, ischaemic 20.02 0.961 20.28 0.446
Cytomegalovirus serology status, donor or recipient positive 0.42 0.332 0.39 0.382
Left ventricular assist device use, yes 20.59 0.198 20.87 0.069
aPositive coefficient indicates a probability of acute cellular rejection ≥3A (2R) increases with specified variable setting; negative coefficient indicates decreased risk of acute cellular
rejection ≥3A (2R).
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Table 7 Univariate analyses of clinical variables for significance of gene-expression profiling score in estimating risks of
≥3A (2R) acute cellular rejection
Covariate ≥3A (2R) rejection (n) Non-rejection (n) P-values
Age
≥54 years 13 447 0.074
,54 years 33 445 0.021
Gender
Male 37 706 0.004
Female 9 186 0.467
Primary indication for cardiac transplantation
Ischaemic 17 326 0.003
Other 29 566 0.164
Cytomegalovirus serology status, donor or recipient positive 0.39
Donor or recipient positive 39 701 0.020
Donor or recipient negative or unknown 7 191 0.107
Left ventricular assist device use
Yes 6 189 0.153
No 40 703 0.011
Reported P-values represent significance of gene-expression profiling score in estimating risks of ≥3A (2R) acute cellular rejection within subsets of patients defined by each
covariate.
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plateau and remains stable from Years 1 to 5 post-transplantation.7
Findings from this study confirmed the GEP score trajectory be-
tween Months 2 and 12 post-transplant. After 12 months, the CAR-
GO II mean GEP scores are much more variable and lower than
observed in the larger database. This discrepancy may be explained
by the small number of samples available from the current study
after 12 months (Figure 2) and patient selection differences between
the studies. The early time dependency of average GEP scores and
acquired practical experience has led many centres to use 34 as the
selected threshold to rule out rejection for patients who are .6–
12 months post-transplantation, and to consider a lower threshold
(e.g. 30) for patients who are 2–6 months post-transplantation.24
The GEP test is ‘intended to aid in the identification of heart trans-
plant recipients with stable graft function who have a low probability
of moderate/severe ACR at the time of testing in conjunction with
standard clinical assessment’ (FDA cleared intended use statement).
Specific threshold values are not designated in the approved label-
ling; rather, the clinician may choose how to select the test score
threshold and make an associated clinical interpretation based on
his/her experience with the test and the overall, comprehensive clin-
ical context of the patient under evaluation. Thus, the complete list-
ing of NPVs and PPVs for each GEP score from 0 to 39 is provided
for the clinician to refer to in considering how a specific test score
may aid in ‘ruling out’ ACR. The threshold of ≥34 was used in the
IMAGE outcomes trial: for patients at least 6 months post-
transplant, a score of ,34 was assumed in IMAGE to be equivalent
to a biopsy diagnosis of no rejection. In addition, useful clinical infor-
mation may also be obtained by considering findings from a series of
GEP scores in a patient, since each patient may serve as his/her own
control of a ‘normal’ GEP score: within patient variability of GEP
scores (after 1 year post-transplantation) may be less than that be-
tween patients.22
As previously characterized in the CARGO study,6 the current
CARGO II results confirmed that the high NPV associated with
GEP scores below a nominal threshold may be reasonably used in
lieu of surveillance biopsies to rule out rejection. The IMAGE3
and E-IMAGE24 studies have demonstrated that the number of sur-
veillance biopsies was safely reduced while the clinical outcomes of
patients managed with GEP surveillance were non-inferior to out-
comes in patients managed with the biopsy strategy.
The results of this study must be interpreted in the context of
some limitations. The study excluded GEP data and biopsies from
visits earlier than 55 days post-transplantation, so the analyses do
not inform us about GEP performance or rejection incidence in
the first 54 days post-transplantation. Also, because patients treated
for rejection within the prior 30 days were excluded, we may have
underestimated the incidence of rejection that might be found in the
entire population. Additionally, in this study, not all GEP tests had
paired biopsy results. Because of the very small number and propor-
tion of clinically suspected, biopsy confirmed, rejections of grade
≥3A (2R), rejections discovered during routine surveillance and re-
jections confirmed with biopsies performed for clinical suspicion
were pooled together in the analyses. These reference rejection
cases, a combination of clinically silent and clinically suspected rejec-
tion, may not have identical GEP signatures. Although the GEP test is
intended for use in a surveillance setting, the discovery of subclinical
rejection is dependent on the frequency of surveillance that varied
at the participating centres. Additionally, the histology grading is an
imperfect reference standard for diagnosis of rejection, although it
remains the clinical standard of care for diagnosis of rejection in
heart transplantation.
The central pathology feature of this study does not reflect prac-
tical clinical care: no clinician relies on obtaining additional histo-
pathology reports from ‘blinded’ independent pathologists to
decide on treatment of a patient. We utilized the central biopsy
reading in this study to enhance the accuracy of diagnostic classifica-
tion of the reference cases. Finally, the question remains whether
GEP scores can be potentially used to optimize a post-transplant im-
munosuppression regimen. This study was not designed to address
that question. Future studies should be conducted to evaluate the
clinical utility of the GEP test to guide immunosuppression medication
intensity to improve long-term outcomes in transplant recipients.
Conclusion
The GEP test performance characteristics in this CARGO II study
are consistent with prior CARGO findings. The low prevalence of
ACR contributes to the high NPV and limited PPV of GEP testing.
Taken together with clinical trial evidence that equivalent clinical
outcomes may be attained in patients managed with GEP compared
with patients managed with biopsies for acute cellular rejection sur-
veillance, the CARGO II results further validate that GEP testing may
be used as part of a non-invasive surveillance strategy to rule out
acute cellular rejection in heart transplant recipients. The choice
of threshold score for practical use of GEP testing to rule out rejec-
tion should consider overall clinical assessment of the patient’s base-
line risk for rejection.
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